he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源地址
上一页:心理百科:春节期间小心疾病
- 2022-05-04癫痫病的较上新都有什么
- 2022-04-25有系统癫痫的先兆研究
- 2022-04-202013年国际抗癫痫总会抗癫痫药使用指南
- 综述:癫痫持续状态诊治最新进展
- Medpage Today:不同类型的抗癫痫药物更有利
- 预测癫痫患者再入院风险
- 英国竞争监管机构指控辉瑞癫痫药品价格过高
- 【用药情报站】临床应用应听取各种药种药物禁忌证?
- 第四届全国临床脑电图实践基础理论与实践操作培训班
- 抗癫痫药物预防新发癫痫:任重而道远
- 心率多少正常 如何保持正常心率不变
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- UCB的Vimpat癫痫新适应症在美国获批
- 癫痫治疗障碍仍难以克服
- 癫痫患者手术评估新型工具
- 泡温泉时不能忽视的事情
- PLoS ONE:新的合成蛋白能快速激活免疫系统抵抗流感
- FDA批准Aptiom用于治疗患者癫痫发作
- 2013国际抗癫痫联合会抗癫痫药用指南
- EMA建议:限制育龄妇女使用丙戊酸盐
- 手术学习:颅内脊索瘤内镜下三脑室入路治疗
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 癫痫发作的症状及急救措施
- 月经期间要注意 有些药物和食物不能食用
- 世界癫痫日 | 科学防治 标准诊疗 告别癫痫
- 上海率先探索异地就医门诊费直接结算
- Neurology:颅脑损伤增加了迟发性癫痫的风险,高损伤频率、重伤、老年人尤其是
- 2015 神经系统疾病诊疗进展
- 癫痫猝死:凶手是谁?
- 2016AAN:神经专家发表具前景的专业见解
- 猪血的做法 老少皆宜的补血佳肴(14)
- 不注意这些问题,吃多少药都只不过!
- 基本上治疗癫痫病医院
- UCB的Vimpat癫痫新适应症在旧金山获批
- 癫痫病的最初症状 患有癫痫万不可吃它(2)
- 先天性癫痫病的哮喘有哪些
- 三德分享的病例:花了三个星期才明确诊断
- 疗法癫痫的费用是多少
- 老人能吃橄榄菜吗 橄榄菜零食怎么做
- Neurology:颅脑损伤增加迟发性哮喘发生风险,高损伤频率、重伤、老年人尤甚
- 治疗癫痫病的最佳病房
- NeuroImage:纤维球全像可用于癫痫疾病进展
- 20130508养生堂:栾国明讲癫痫病的20世纪症状